• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

    1/9/25 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email

    TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, "Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model," in the peer-reviewed Journal of Vascular and Interventional Radiology. The study, conducted in a transgenic tumor model, highlights the superior performance of the TriNav Infusion System in delivering Embospheres® into liver tumors when compared to delivery with a traditional microcatheter.

    Key Findings:

    • Improved Tumor Penetration: PEDD achieved a 227 % increase (p=0.029) in the concentration of fluorescently labeled Embospheres within tumor tissue compared to a traditional microcatheter.
    • Improved Tumor Selectivity: The tumor-to-normal (T:N) ratio rose from 2.7 for a traditional microcatheter to 4.2 when delivered by PEDD, indicating more precise tumor targeting and reduced off-target delivery.
    • Increased Peritumoral Delivery: Delivery to peritumoral regions increased by 209% (p=0.045), demonstrating PEDD's ability to overcome challenging tumor associated microenvironments.

    "This study further validates the potential of TriNav using the PEDD approach to transform the treatment of liver tumors," said Bryan F. Cox, Ph.D., Chief of Research for TriSalus. "By significantly enhancing therapeutic delivery and sparing healthy tissue, PEDD offers a promising advancement for patients whose outcomes may be limited by conventional delivery methods."

    The study was conducted using a transgenic porcine (Oncopig) liver tumor model, employing fluorescent imaging and advanced deep-learning algorithms to quantify therapeutic delivery with millimeter-scale resolution. Results showed the TriNav Infusion System using the PEDD approach markedly outperforms traditional microcatheters in delivering embolic microspheres into liver tumors.

    These findings add to the growing body of clinical and real-world evidence supporting PEDD's ability to improve the delivery of therapeutic agents for patients with primary and metastatic liver cancers.

    To read the full study, visit here.

    About TriSalus Life Sciences

    TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutic delivery to solid tumors. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors as well as other solid tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of infusion into solid tumors. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to limit delivery to normal tissue, creating the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.

    In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.

    Forward-Looking Statements

    Certain statements made in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "become," "may," "intend," "will," "expect," "anticipate," "believe" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding TriSalus's business, the commercial potential of its TriNav Infusion System, TriSalus's proprietary PEDD approach, the potential therapeutic benefits and commercial potential of Nelitolimod, and TriSalus's technologies and other products in development. Such statements are subject to certain risks and uncertainties, including, but not limited to, those inherent in the process of developing and commercializing medical devices that are safe and effective for human use, discovering, developing and commercializing medicines that are safe and effective to use as human therapeutics, and the endeavor of building a business around such medical devices and medicines.

    TriSalus's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although TriSalus's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by TriSalus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning TriSalus's products and programs are described in additional detail in TriSalus's annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission (the "SEC") and available at the SEC's website (www.SEC.gov). These forward-looking statements are made as of the date of this press release, and TriSalus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250109060433/en/

    For Media Inquiries:

    Jeremy Feffer, Managing Director

    LifeSci Advisors

    917.749.1494

    [email protected]

    For Investor Inquiries:

    James Young

    Chief Financial Officer

    847.337.0655

    [email protected]

    Get the next $TLSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Leadership Updates

    Live Leadership Updates

    See more
    • TriSalus Life Sciences Announces Key Appointments to Board of Directors

      HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga

      2/3/25 4:05:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Announces Leadership Changes

      James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp

      1/8/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

      TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other

      9/26/24 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/6/25 6:09:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/31/25 5:54:39 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:15:05 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

      Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results fo

      5/15/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

      Conference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the web

      5/12/25 4:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

      Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Support Strategic Vision TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and techn

      4/30/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett was granted 13,175 shares, increasing direct ownership by 36% to 49,663 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:37:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief of Research Cox Bryan F. was granted 15,722 shares and sold $24,678 worth of shares (4,764 units at $5.18), increasing direct ownership by 10% to 119,415 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:33:13 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief of Clinical Operations Devlin Jodi was granted 24,131 shares and sold $24,678 worth of shares (4,764 units at $5.18), increasing direct ownership by 58% to 52,764 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:31:57 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Financials

    Live finance-specific insights

    See more
    • TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

      Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results fo

      5/15/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

      Conference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the web

      5/12/25 4:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

      Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv

      3/27/25 7:30:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on TriSalus Life Sciences

      Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

      2/13/25 8:48:50 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

      12/17/24 8:31:30 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

      ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

      11/11/24 7:48:55 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      12/4/24 4:00:06 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      10/21/24 8:25:05 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by TriSalus Life Sciences Inc.

      10-Q - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/15/25 7:54:52 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/15/25 7:34:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form D filed by TriSalus Life Sciences Inc.

      D - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/8/25 4:19:26 PM ET
      $TLSI
      Medical Specialities
      Health Care